400-859-2883
Your location:Home >News center >Industry News

Industry News

11-182023

List of FDA Approved PEGylated Drugs Up t…

History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.

List of FDA Approved PEGylated Drugs Up to 2024
12-122024

ROR1: A Promising Target for Cancer Thera…

Recent clinical trial data presented at the 66th American Society of Hematology (ASH) Annual Meeting, especially regarding zilovertamab vedotin and CS5001, has attracted considerable attentio…

ROR1: A Promising Target for Cancer Therapy
11-252024

PEG Based Hydrogels for Medical Devices

Several leading companies worldwide have introduced medical devices based on PEG hydrogel.

PEG Based Hydrogels for Medical Devices
11-152024

Myasthenia Gravis (MG) Treatments - FcRn …

Now, there 5 approved drugs for the treatment of Myasthenia Gravis.

Myasthenia Gravis (MG) Treatments - FcRn Antagonists & Complement Inhibitors
10-252024

What is the difference between siRNA and …

On October 7, 2024, the Nobel Prize in Physiology or Medicine was awarded to Professor Victor Ambros from the University of Massachusetts Medical School and Professor Gary Ruvkun from Harvard…

What is the difference between siRNA and miRNA
10-132024

Use of Monodisperse PEGs to Accelerate Dr…

Monodisperse PEG, which consists of uniform molecules with precise, discrete molecular weights and well-defined configurations, offers a solution to these issues.

Use of Monodisperse PEGs to Accelerate Drug Development
09-272024

Latest Clinical Data on Obesity Drugs and…

Next, we will focus on the latest clinical data for obesity drugs and provide a comprehensive overview of available weight loss medications.

Latest Clinical Data on Obesity Drugs and Overview of Popular Weight Loss Medications
09-132024

Overview of Long Acting Growth Hormone Fo…

Developing long-acting growth hormone (LAGH) formulations to improve adherence and treatment outcomes has become a primary focus.

Overview of Long Acting Growth Hormone Formulations
08-272024

Dual/Triple-Agonists Targeting GLP-1R

The success of tirzepatide has made GLP-1 dual/triple agonists a hot area of competition.

Dual/Triple-Agonists Targeting GLP-1R
08-092024

New Advances of Antibody-Drug Conjugates …

Among the many ADCs in development, several companies are actively seeking unique breakthroughs to stand out. Lets explore these companies innovative approaches.

New Advances of Antibody-Drug Conjugates (ADCs)